Sökning: onr:"swepub:oai:DiVA.org:oru-47313" >
Entacapone and pros...
Entacapone and prostate cancer risk in patients with Parkinson's disease
-
- Korhonen, Pasi (författare)
- EPID Research Oy, Espoo, Finland
-
- Kuoppamäki, Mikko (författare)
- Orion Pharma, Orion Corporation, Espoo, Finland
-
- Prami, Tuire (författare)
- EPID Research Oy, Espoo, Finland
-
visa fler...
-
- Hoti, Fabian (författare)
- EPID Research Oy, Espoo, Finland
-
- Christopher, Solomon (författare)
- EPID Research Oy, Espoo, Finland
-
- Ellmen, Juha (författare)
- Orion Pharma, Orion Corporation, Espoo, Finland
-
- Aho, Valtteri (författare)
- Orion Pharma, Orion Corporation, Espoo, Finland
-
- Vahteristo, Mikko (författare)
- Orion Pharma, Orion Corporation, Espoo, Finland
-
- Pukkala, Eero (författare)
- Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland; School of Health Sciences, University of Tampere, Tampere, Finland
-
- Haukka, Jari (författare)
- EPID Research Oy, Espoo, Finland
-
- Tuvblad, Catherine, 1968- (bidragsgivare)
- Örebro universitet,Institutionen för juridik, psykologi och socialt arbete,CAPS
-
visa färre...
-
(creator_code:org_t)
- 2015-01-16
- 2015
- Engelska.
-
Ingår i: Movement Disorders. - Hoboken, USA : Wiley-Blackwell. - 0885-3185 .- 1531-8257. ; 30:5, s. 724-728
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: The association between Parkinson’s disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol-O-methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.Methods: We performed a retrospective cohort study using population-wide health care registers with patientlevel linkage. Prostate cancer incidence and mortality were modeled by Cox’s proportional hazards models.Results and Conclusions: Use of entacapone with Ldopa/dopa decarboxylase inhibitor caused no increased risk of prostate cancer incidence (hazard ratio [HR]: 1.05; 95% confidence interval: 0.76-1.44) or mortality (0.93; 0.43-1.98). The HR for cumulative entacapone use of >360 days versus never-use was 0.82 (0.56-1.18) for prostate cancer incidence and 1.27 (0.60-2.72) for prostate cancer mortality.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Entacapone
- evodopa
- prostate cancer
- pharmacoepidemiology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Korhonen, Pasi
-
Kuoppamäki, Mikk ...
-
Prami, Tuire
-
Hoti, Fabian
-
Christopher, Sol ...
-
Ellmen, Juha
-
visa fler...
-
Aho, Valtteri
-
Vahteristo, Mikk ...
-
Pukkala, Eero
-
Haukka, Jari
-
Tuvblad, Catheri ...
-
visa färre...
- Om ämnet
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
och Clinical Medicin ...
-
och Cancer and Oncol ...
- Artiklar i publikationen
-
Movement Disorde ...
- Av lärosätet
-
Örebro universitet